6533b82efe1ef96bd1292832

RESEARCH PRODUCT

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance

Dolores IslaJosé Miguel Sánchez-torresRichard B. LanmanIris FaullSantiago Ponce-aixEnriqueta FelipPilar GarridoO. Juan-vidalRosario García-campeloCarlos CampsInmaculada RamosAna Gómez-ruedaEloisa Jantus-lewintreLuis Paz-aresR. BernabéJon ZugazagoitiaJose Manuel TrigoMariano ProvencioJavier De Castro

subject

0301 basic medicineOncologyMaleCancer ResearchLung NeoplasmsTyrosine-kinase inhibitorCirculating Tumor DNAchemistry.chemical_compound0302 clinical medicineCarcinoma Non-Small-Cell LungMedicineOsimertinibNeoplasm MetastasisProspective cohort studyAged 80 and overDisease ManagementHigh-Throughput Nucleotide SequencingMiddle AgedOncology030220 oncology & carcinogenesisFemalemedicine.drugPulmonary and Respiratory MedicineAdultmedicine.medical_specialtyCabozantinibmedicine.drug_class03 medical and health sciencesInternal medicineROS1Biomarkers TumorHumansLung cancerProtein Kinase InhibitorsAgedNeoplasm StagingDigital next-generation sequencingTKI resistanceCrizotinibbusiness.industryOncogene-driven NSCLCOncogenesctDNAmedicine.diseaseLorlatinibrespiratory tract diseases030104 developmental biologychemistryDrug Resistance NeoplasmMutationbusinessOsimertinib

description

[Objectives] Resistance to tyrosine-kinase inhibitors (TKIs) is a clinical challenge in patients with oncogene-driven non-small-cell lung cancers (NSCLC). We have analyzed the utility of next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA) to impact the clinical care of patients with TKI resistance.

yearjournalcountryeditionlanguage
2019-08-01
10.1016/j.lungcan.2019.05.032http://hdl.handle.net/10261/213437